Financials & Transparency

ARMoR is a global health non-profit launched in September 2023 through the Ambitious Impact Incubation Programme. We work to combat antimicrobial resistance (AMR) by combining rigorous research with strategic advocacy, helping governments and institutions implement policies that drive the development and global accessibility of life-saving antimicrobials.

Drug-resistant infections kill over 1 million people each year.

Without urgent action, AMR is projected to cause an extra 39M deaths between now and 2050.

Financial Independence

To safeguard independence of decision-making, ARMoR does not accept funding from pharmaceutical or biotech companies. Furthermore, we do not sell products nor we profit from the policies we endorse.

Our Funding

(Sep 2023 – Mar 2025)

From our launch in September 2023 to March 2025, ARMoR has received $226,477 in total funds. This includes philanthropic support and revenue from mission-aligned consulting projects.

ARMoR is a project of Charity Entrepreneurship operating through a fiscal sponsorship with Players Philanthropy Fund (Federal Tax ID: 27-6601178, ppf.org/pp), a Maryland charitable trust with federal tax-exempt status as a public charity under Section 501(c)(3) of the Internal Revenue Code.

Contributions to ARMoR qualify as tax-deductible to the fullest extent of the law.